Chesapeake Clinical Research, Inc.

04/26/2023

Asthma Research Study for people diagnosed with asthma designed to take place in the comfort of your
home!
The BATURA study is looking for participants who have been diagnosed by a healthcare professional
with asthma and are using a rescue inhaler – with or without other medication - to control their asthma
symptoms. The study drug is administered through (or delivered by) an inhaler that combines two drug
components that have been used in asthma with separate inhalers for over 30 years. Although the
individual drug components are approved and in separate inhalers, the combination of drugs in one
inhaler is being evaluated for effectiveness and safety.
Individuals may qualify for the study if they:
• Are 12 years of age and older*
• Have had a clinical diagnosis of asthma, by a healthcare professional
Home
• Are actively using Short-acting Beta-agonist inhalers (as-needed rescue inhaler, such as
albuterol) to control or reduce asthma symptoms, alone or in combination with either low dose
inhaled corticosteroid (Flovent®, Pulmicort®, or Asmanex®) or leukotriene inhibitor
montelukast (Singulair), zileuton (Zyflo®), or zafirlukast (Accolate®).
• Meet additional study criteria.
*Parental consent is required for individuals under 18 years of age.
This study does not require in-person visits to a study site. Appointments with your study doctor and
other team members will take place using an online video meeting using your mobile phone or
computer. No travel is involved and the study drug and all study-related care will be delivered to your
home at no cost.
Call 410-931-1966 x 101 and speak to our recruiter Michelle.

09/19/2022

Want to find out about more potential new treatment options for people with nasal polyps? The ORCHID Study is researching a potential new medication that is not yet approved by regulatory authorities and can only be given to people as part of a clinical trial like this.

Eligible participants may receive compensation for study-related travel expenses.

You may be able to participate in the study if you:
• are 18-75 years of age
• have been diagnosed with nasal polyps and asthma

To learn more, please visit: Geri Novak 410-931-1966 x103

09/19/2022

09/19/2022

Do You Suffer From
Chronic Hives?

A new treatment is on the horizon.

Introducing CDX-0159-06:

A phase 2 study, currently seeking participants diagnosed
with Chronic Spontaneous Urticaria (CSU).

— NOW ENROLLING PARTICIPANTS —

This study aims to evaluate the long-term effectiveness and safety of CDX-0159 in the treatment of CSU symptoms. CDX-0159 has already shown great promise, and further research is needed to advance efforts to help people with CSU.

Your participation in this study will help to:

•
Determine the effectiveness of different dosing regimens of CDX-0159 for people with CSU
•
Determine the dose regimens that most effectively reduce itch severity
•
Determine the dose regimens that most effectively reduce the severity of hives
Let’s Find a Solution for Your Discomfort… Together.

Contact Geri Novak at 410-931-1966 x103

09/19/2022

Are you interested in taking part in a clinical study?

We are looking for patients who have Chronic Obstructive
Pulmonary Disease (COPD), also known as emphysema or chronic
bronchitis, to take part in a clinical study called FRONTIER 4.

FRONTIER 4 will be investigating whether a treatment called MEDI3506 may provide benefit to patients with COPD.

Who can join?

You may be suitable for FRONTIER-4 if you:
Have COPD
Are a current or ex-smoker
Have experienced 1 or more exacerbations (where symptoms
are much worse than usual) in the past 2 years
Are between 40 and 80 years of age

What will the study involve?

During the study, you will be asked to attend
appointments that may include:
Physical examinations
Lung function tests
Tests such as blood and urine samples and heart tests *ECG, electrocardiogram; ECHO, echocardiogram
†CT, computed tomography.
Collection of nasal tissue and sputum samples
A well-being questionnaire
You will be asked to complete a daily e-Diary and some lung-function tests at home.

If you are interested in taking part in the FRONTIER 4 study,
please speak with your doctor for more information.

Contact: Geri Novak 410-931-1966 x103

01/06/2022

We are currently testing for Covid-19/Influenza A&B/RSV We are looking for RSV-adults over 18 to 85 who have any of these: Asthma, Congestive Heart Failure, COPD or are over the age of 65 and are symptomatic but non-severe symptoms during the last 24 hrs. Please call for information, appt. drive up testing. Please read below. Chesapeake Clinical Research, Inc. 5430 Campbell Blvd., Suite 110, White Marsh, Maryland 21162
Phone: 410-931-1966

12/14/2021

Chesapeake Clinical Research is conducting a study for RSV: Pre Study Testing will be a nasal swab that will test for Covid, Flu and RSV curbside.
What is RSV?
Respiratory syncytial virus, or RSV, has
symptoms similar to the common cold, flu,
or COVID. The initial symptoms can include
runny or stuffy nose, sore throat, coughing,
sneezing, and/or fever.
While RSV can cause upper and lower
respiratory illness in everybody, some
people are at a higher risk for developing
more severe RSV disease and RSV-related
complications, as well as being hospitalized.
These high-risk adults include anyone who is
65 years of age or older or has chronic heart
failure, COPD, or asthma.
Researchers in the PRIMROSE study want to assess whether
an investigational RSV medicine is safe and effective for
adults at risk for more severe RSV infection. They want to
compare the investigational medicine to placebo, which looks
like the investigational medicine but does not contain the
active medicine.
The investigational medicine has not been approved to treat
RSV and is available only in research studies like this one. The
results of this study may provide more information about the
investigational medicine when it is given to high-risk adults.
Who is eligible to participate in
the PRIMROSE study?
To pre-qualify for this study, you must:
• Be 18 to 85 years of age
• Have one of the following risk factors for severe RSV
disease and complications: 65 years of age or older,
chronic heart failure, COPD, or asthma
• Not be currently hospitalized
If you are interested, additional criteria will be assessed
by the study doctor. Qualified patients may receive study
medicine and some study-required medical care at
no cost.
As soon as you experience respiratory or cold/flu-like
symptoms or worsening of your underlying symptoms, or
to learn more about the PRIMROSE study, you may contact us
directly.
What will happen during the
PRIMROSE study?
If you are eligible for and agree to participate in this study,
you will be randomly assigned (like rolling the dice) to receive
the investigational medicine or placebo.
You have a 2 in 3 chance (67%) of receiving the investigational
medicine and a 1 in 3 chance (33%) of receiving placebo.
Neither you nor the study doctor/staff will know if you are
receiving the investigational medicine or placebo. However, in
the event of an emergency, this information can be provided.
All patients will take their assigned study medicine
(investigational or placebo) twice a day for 7 days. You may be
asked to visit the study clinic up to 8 times. Some study clinic
visits could take place at your home or be phone calls from
the study doctor/staff.
Total participation in this study will last about 35 days, which
includes screening for eligibility, taking your study medicine,
and follow-up.
What are the benefits and risks
related to the PRIMROSE study?
There is no guarantee you will benefit from participating in
this study. However, your participation could help people with
RSV in the future. By participating in this research, you may
learn more about respiratory infections.
It is possible you could experience side effects while
participating in this study. The study staff will review all
known study-related risks and side effects with you
prior to beginning the study.
Currently, there is no medicine approved to treat RSV
infection in adults. Treatment is limited to caring for
a patient’s symptoms. Consequently, researchers are
searching for other solutions that treat RSV itself.

Please call Chesapeake Clinical Research for more information: 410-931-1966

10/23/2020

Chesapeake Clinical Research, Inc. is looking for volunteers to participate in a new grass pollen allergy study. Earn up to $2258. People who have experienced troublesome to very troublesome allergy symptoms despite using anti-allergy medication for the last two years may be eligible. We are seeking males and females ages 18-65 years old. Join our research study and help to find a new therapy for seasonal grass allergies. Contact Michelle Sprecher at 410-931-1966 x101.

10/23/2020

Current and Upcoming Studies include asthma, COPD, and grass allergies! If you're interested in more information, please call: 410-931-1966 x 101